India, Oct. 15 -- On Thursday, Eli Lilly and Company (LLY), a pharmaceutical company, reported new one-year data showing that patients treated with Omvoh (mirikizumab-mrkz) achieved comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease.
Company Profile
Lilly develops medicines across several therapeutic areas, including diabetes, obesity, immunology and oncology. Omvoh is an interleukin-23p19 (IL-23p19) antagonist approved for adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease.
Omvoh Clinical Data HighlightsIn a post-hoc analysis of the Phase 3 LUCENT-2 study, 27.7% of Omvoh-treated patients with UC achieved comprehensive disease control at one yea...